Layn: The RebM2 product is expected to become a new profit growth point for the company in the future

On August 19, Layn stated on the interactive platform that in the domestic market, the draft for public consultation of the steviol glycoside RebM2, which the company has applied for as a new type of food additive, ended on August 14, and the company is actively promoting the subsequent approval work; in the overseas market, RebM2 passed the US FDA GRAS certification in February this year and can be legally sold in the US food and beverage market. The RebM2 product was exclusively developed by the company's R&D team and is expected to become a new profit growth point for the company in the future